Retrospective Analysis of Real-World Transition Strategies for Xanomeline and Trospium Chloride in Adult Patients With Schizophrenia
Background: Approximately 30%-50% of adults with schizophrenia switch antipsychotic medication within 6-24 months of treatment initiation. This study aims to analyze retrospective real-world data from psychiatry healthcare providers (HCPs) to describe the methodology utilized in successfully transitioning adults with schizophrenia from other antipsychotic medications to xanomeline and trospium chloride (X/T).
Methodology: This retrospective study of adults with schizophrenia who have transitioned to X/T after previous treatment with a typical or atypical antipsychotic was conducted using an electronic survey sent to psychiatry HCPs. Successful transition was defined as maintained treatment with X/T for ≥1 month with no discontinuation. Data were de-identified at the time of collection.
Results: Data collection is ongoing. Demographics for the first interim evaluation of 50 patients were 66% male, 78% Caucasian, 8% African American, and 8% Hispanic/Latino. Top reasons for previous antipsychotic medication discontinuation were lack of adequate control of positive symptoms and worsened negative symptoms. The majority transitioned using a cross-titration approach over 2-4 weeks with half being cross-titrated at 50% reduction of baseline over 2 weeks; to date, 28% of patients have been on X/T for >24 weeks. Most HCPs (78%) provided their patients with an antiemetic either as a prophylactic treatment or as needed if nausea/vomiting occurred.
Conclusion: A variety of real-world strategies have been implemented by HCPs to transition adults with schizophrenia to the novel treatment X/T. Most common strategies utilized in successful switches include cross-titration and consideration of an antiemetic medication for the transient nausea and vomiting that may occur during titration.
